| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
37,449 |
31,996 |
$687K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,111 |
1,087 |
$138K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,357 |
1,316 |
$67K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
672 |
572 |
$8K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
60 |
54 |
$7K |
| 90834 |
Psychotherapy, 45 minutes with patient |
805 |
299 |
$7K |
| 99205 |
Prolong outpt/office vis |
56 |
55 |
$3K |
| 20552 |
|
53 |
50 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
27 |
24 |
$563.57 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
140 |
119 |
$225.02 |
| 96127 |
|
77 |
63 |
$104.56 |
| 90791 |
Psychiatric diagnostic evaluation |
14 |
12 |
$81.80 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
111 |
94 |
$12.80 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
30 |
26 |
$5.94 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
12 |
12 |
$0.60 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
11,977 |
10,107 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
2,860 |
2,538 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
354 |
255 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,253 |
1,016 |
$0.00 |
| 99072 |
|
199 |
178 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
51 |
46 |
$0.00 |
| G8541 |
Functional outcome assessment using a standardized tool not documented, reason not given |
135 |
120 |
$0.00 |
| G9905 |
Patient not screened for tobacco use |
128 |
91 |
$0.00 |
| G8938 |
Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible |
13 |
13 |
$0.00 |
| G8421 |
Bmi not documented and no reason is given |
175 |
143 |
$0.00 |
| 3288F |
|
146 |
140 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
14 |
14 |
$0.00 |
| G8511 |
Screening for depression documented as positive, follow-up plan not documented, reason not given |
35 |
34 |
$0.00 |
| 99442 |
|
21 |
14 |
$0.00 |
| 99490 |
Ccm add 20min |
12 |
12 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
1,991 |
1,591 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
216 |
190 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,265 |
1,030 |
$0.00 |
| G8432 |
Depression screening not documented, reason not given |
323 |
270 |
$0.00 |
| 1123F |
|
312 |
260 |
$0.00 |
| 1036F |
|
35 |
29 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
170 |
144 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
76 |
67 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
13 |
12 |
$0.00 |
| G8422 |
Bmi not documented, documentation the patient is not eligible for bmi calculation |
52 |
39 |
$0.00 |
| 1101F |
|
24 |
22 |
$0.00 |